J&J’s US OTC Sales Hold Firm As COVID Impact Begins To Bite
Johnson & Johnson US OTC sales a bright spot in a Q2 performance hampered by the COVID-19 pandemic.
You may also be interested in...
April-June sales of OTC drugs, supplements and personal care products likely will show at least notable and potentially strong increases from year-ago period when consumers slowed spending after splurging during 2020 Q1 as novel coronavirus pandemic sent shockwaves through the marketplace.
Iconic brand could have spurred consumer interest and helped drive 15.2% US sales growth for its wound care business with the launch earlier in 2020 of strips in hues that better match the skin tones of black and brown customers.
Johnson & Johnson skin health includes hard-hit products and products that have seen double-digit sales growth during the pandemic, worldwide chairman of Consumer Health Thibaut Mongon said at the Barclays Global Consumer Staples Conference. He went on to highlight launches that are reinforcing J&J’s lead in therapeutic skin care and reflecting its sustainability push.